Archer Materials (ASX:AXE) advanced to the next stage of product development via the construction of its beta prototype Biosensor platform suitable for preclinical validation, after its integrated alpha prototype medical device achieved clinical-grade potassium sensing accuracy, according to a Friday Australian bourse filing.

It plans to develop multiple versions of the beta prototype. The first beta prototype system is expected to become available for testing in the coming months. Early feasibility testing for monitoring lithium levels in blood is underway.

Additional optimization and validation are planned throughout the second half of the year, with the target of a fully optimized beta prototype for use in trials in 2027.

Its shares climbed 3% in recent trading on Friday.